Patents by Inventor Sun Woo Im
Sun Woo Im has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951130Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: March 1, 2021Date of Patent: April 9, 2024Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Patent number: 11905334Abstract: It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.Type: GrantFiled: February 5, 2021Date of Patent: February 20, 2024Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
-
Publication number: 20230242607Abstract: An interleukin (IL)-2 protein including a sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, and SEQ ID NO: 18. A pharmaceutical composition including the interleukin-2 protein and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 7, 2021Publication date: August 3, 2023Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Seoung Hyun LEE, Sun Woo IM, Jin Kyung CHOI, Hyun Tae SON, Joong Won LEE, Hanna LEE, Sunhee HWANG
-
Publication number: 20230151113Abstract: Provided herein are CAR-T compositions that are directed to GPC3, including a chimeric receptor, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells, optionally in combination with expression of IL-18. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.Type: ApplicationFiled: March 18, 2021Publication date: May 18, 2023Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Kwanghee KIM, Jiwon CHUNG, Young Gyoon CHANG, Bo-Rim YI, Jungyun LEE, Seunghyun LEE, Sun-Woo IM, Jinkyung CHOI, Hyuntae SON, Hye Mi LEE
-
Publication number: 20230146706Abstract: Provided are CAR-T compositions that are directed to GPC3, including chimeric receptors, and engineered immune cells to GPC3. The disclosure also provides vectors, compositions, and methods of treatment using GPC3 antigen binding molecules and engineered immune cells. GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.Type: ApplicationFiled: March 18, 2021Publication date: May 11, 2023Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Kwanghee KIM, Jiwon CHUNG, Young Gyoon CHANG, Bo-Rim YI, Jungyun LEE, Seunghyun LEE, Sun-Woo IM, Jinkyung CHOI, Hyuntae SON, Hye Mi LEE
-
Publication number: 20220275083Abstract: The present invention provides a bispecific epitope binding protein comprising an anti-4-1BB agonist antibody and a PD-1 protein or a fragment thereof that binds to PD-L1 with high affinity. The bispecific epitope binding protein simultaneously and independently binds to 4-1BB and PD-L1, which engage 4-1BB upregulated T cells, especially effector CD8+ T cells, with tumor cells expressing PD-L1. These interactions induce strong activation of the cytotoxic activity of anti-tumor effector CD8+ T cells by both blocking PD-1/PD-L1-mediated inhibitory signaling and activating 4-1BB-mediated costimulatory signaling in mouse models. This bispecific epitope binding protein has a much stronger oncolytic effect compared to each component alone.Type: ApplicationFiled: January 11, 2022Publication date: September 1, 2022Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Hanna LEE, Jin Sung PARK, Seung Hee HAN, Hyun Tae SON, Sun Woo IM, Hyeok-Jun PARK, Eunhye YOO, Sung Min PARK, Yeonji OH
-
Publication number: 20220073586Abstract: Provided are PD-1 polypeptide variants including an extracellular domain that binds specifically to PD-L1, and a transmembrane domain or a fragment thereof. The disclosure also provides PD-1 Fc fusion proteins including an immunoglobulin Fc region, and a PD-1 polypeptide variant.Type: ApplicationFiled: September 8, 2021Publication date: March 10, 2022Applicant: EUTILEX CO., LTD.Inventors: Byoung S. KWON, Seunghyun LEE, Hanna LEE, Jin Sung PARK, Jin Kyung CHOI, Seung Hee HAN, Sun Woo IM, Hyun Tae SON
-
Publication number: 20220031742Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: ApplicationFiled: March 1, 2021Publication date: February 3, 2022Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Publication number: 20210261681Abstract: It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.Type: ApplicationFiled: February 5, 2021Publication date: August 26, 2021Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
-
Patent number: 11013765Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: December 16, 2019Date of Patent: May 25, 2021Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Patent number: 10927183Abstract: Provided are antibodies and antigen-binding fragment thereof that bind to VSIG4. Various in vitro and in vivo methods and compositions related to antibodies. Methods include prevention and/or therapeutic treatment of cancer using an antibody or an antigen-binding fragment that binds to VSIG4.Type: GrantFiled: April 2, 2020Date of Patent: February 23, 2021Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
-
Publication number: 20200291126Abstract: Provided are antibodies and antigen-binding fragment thereof that bind to VSIG4. Various in vitro and in vivo methods and compositions related to antibodies. Methods include prevention and/or therapeutic treatment of cancer using an antibody or an antigen-binding fragment that binds to VSIG4.Type: ApplicationFiled: April 2, 2020Publication date: September 17, 2020Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
-
Publication number: 20200237821Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: ApplicationFiled: December 16, 2019Publication date: July 30, 2020Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Patent number: 8643299Abstract: An LED lamp driving circuit includes: a thermistor having one terminal through which an external voltage is applied; an AC-DC conversion unit connected to the other terminal of the thermistor and converting an AC voltage applied to the other terminal of the thermistor into a DC voltage; and a DC-DC conversion unit converting the DC voltage from the AC-DC conversion unit into a DC voltage required to drive the LED lamp.Type: GrantFiled: April 1, 2011Date of Patent: February 4, 2014Assignee: Samsung Electronics Co., Ltd.Inventors: Yong Keun Jee, Byung Kwan Song, Yun Whan Na, Jin Jong Kim, Sun Woo Im, Seok Kyu Kim, Hyun Kyung Kim
-
Publication number: 20120038289Abstract: An LED lamp driving circuit includes: a thermistor having one terminal through which an external voltage is applied; an AC-DC conversion unit connected to the other terminal of the thermistor and converting an AC voltage applied to the other terminal of the thermistor into a DC voltage; and a DC-DC conversion unit converting the DC voltage from the AC-DC conversion unit into a DC voltage required to drive the LED lamp.Type: ApplicationFiled: April 1, 2011Publication date: February 16, 2012Inventors: Yong Keun Jee, Byung Kwan Song, Yun Whan Na, Jin Jong Kim, Sun Woo Im, Seok Kyu Kim, Hyun Kyung Kim